Current Research Studies
An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD)
Belumosudil for Ped cGVHD
What is the goal of the study?
This is a drug study that will explore the safety and efficacy of a novel oral suspension of belumosudil in children between the ages of 1 and < 18 years. The primary objectives of this study are to establish the recommended pediatric equivalent dose of belumosudil and to evaluate overall response rate by 24 weeks.
Who can participate in the study?
Please contact the study team listed below to learn more.